Licensed, off-label, and Specials are three regulatory categories of medicine use in UK telehealth. Licensed use is the default — the medicine is used as approved by MHRA for the licensed indication. Off-label use is using a licensed medicine outside its approved indication, requiring individual clinical justification. Specials use is unlicensed medicines for individual patient need. Each category has different regulatory expectations.
Licensed medicines — the default
A licensed medicine in the UK has been authorised by MHRA following the manufacturer's submission of data on safety, efficacy, and quality. The licence specifies the medicine's approved indications, dosage, contraindications, and labelling. Prescribing within the licence is the default — clinically straightforward and regulatorily least complex.
Most UK telehealth prescribing is licensed-indication prescribing. Finasteride for male pattern hair loss within licensed dose; sildenafil for ED within licensed dose; HRT preparations for menopause; SSRIs for depression. The clinical decision still requires proper assessment, but the regulatory framework is the standard one.
Off-label use — licensed medicines outside their approved indication
Off-label use is permitted in UK practice — including telehealth — but requires individual clinical justification documented in the patient record. Examples in UK telehealth: oral minoxidil at low dose for hair loss (not licensed for this indication), certain HRT regimens for menopause symptom management outside licensed approach, off-label SSRIs in adolescent patients.
Off-label without documented per-patient justification is the enforcement pattern MHRA has targeted. Brands operating off-label at scale without per-patient clinical justification — for example, systematically prescribing off-label for a category without individual review — attract attention. The fix is structural: ensure clinical justification is documented every time.
Specials — unlicensed medicines for individual patient need
The Specials regime permits supply of unlicensed medicinal products to meet the special clinical needs of an individual patient where no licensed alternative is suitable. Specials use requires: documented individual patient need, prescriber justification that no licensed alternative is suitable, MHRA notification, and proper supply governance through a Specials-authorised manufacturer or importer.
Examples: certain compounded preparations not available in licensed form, paediatric formulations of medicines licensed only in adult forms, certain specific dosages not commercially produced. Specials is patient-specific, not a general route to alternative formulations.
How the three categories interact in telehealth practice
A well-run UK telehealth service uses all three categories where appropriate. Licensed prescribing is the default and the majority of activity. Off-label prescribing is documented case-by-case where clinical reasoning supports it. Specials are used in defined patient-specific circumstances under proper regime.
What separates compliant services from problematic ones: the documentation and the discipline. Compliant services document the clinical reasoning, justify the choice, and operate the regulatory frameworks correctly. Problematic services blur the categories and treat the regulatory distinctions as paperwork.
How PExpo handles licensed, off-label, and Specials supply
PExpo's dispensing operation handles all three categories under proper governance. Licensed medicines are dispensed as the default through standard UK supply chains. Off-label prescribing decisions are documented in the patient record with clinical justification. Specials regime medicines are supplied under MHRA notification and proper clinical justification.
Brands operating with PExpo do not need to build the regulatory infrastructure for each category separately — the framework is integrated. See our brand model page for the operational scope.
Off-label prescribing without documented per-patient clinical justification is a known MHRA enforcement pattern. Build documentation discipline into the clinical workflow before launch — not after the first inspection.
Compliant services document the clinical reasoning, justify the choice, and operate the regulatory frameworks correctly. Problematic services blur the categories and treat the regulatory distinctions as paperwork.
Licensed, off-label, and Specials are three regulatory categories of medicine use in UK telehealth. Each has its place; each requires the appropriate documentation and discipline. Compliant brands use all three where clinically justified. Problematic brands blur the categories. See our brand model page for how PExpo's dispensing handles each category and our pricing page for the commercial structure.
Frequently asked questions
Can I prescribe a licensed medicine off-label in UK telehealth?
Yes — off-label prescribing is permitted in UK practice with documented individual clinical justification per patient. The documentation is the critical operational element.
How do I tell if a medicine is licensed for a specific indication?
Check the Summary of Product Characteristics (SmPC) — the official document listing approved indications, dosing, contraindications, and warnings. SmPCs are publicly available via emc.medicines.org.uk.
Does PExpo handle Specials regime supply?
Yes — where category demand or patient need requires unlicensed Specials-route products, PExpo's pharmacy operates within the Specials regime under MHRA notification and proper clinical justification. See our brand model page.
